Ruud Oerlemans

1.5k citations

23 papers · 1.2k indexed · h-index 13

Co-authors: Gerrit Jansen Rik J. Scheper Ben A. C. Dijkmans Joost W van der Heijden George L. Scheffer Yehuda G. Assaraf Willem F. Lems Godefridus J. Peters
Topics: Drug Transport and Resistance Mechanisms (8 papers)Rheumatoid Arthritis Research and Therapies (6 papers)Multiple Myeloma Research and Treatments (5 papers)
Cited by: Hematology Oncology Rheumatology
Journals: Blood Journal of Pharmacology and Experimental Therapeutics Annals of the Rheumatic Diseases
Partner nations: Netherlands Israel United States

In The Last Decade

Ruud Oerlemans

22 papers receiving 1.1k citations

Peers

Countries citing papers authored by Ruud Oerlemans

Since Specialization

Citations

This map shows the geographic impact of Ruud Oerlemans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruud Oerlemans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruud Oerlemans more than expected).

Fields of papers citing papers by Ruud Oerlemans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruud Oerlemans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruud Oerlemans. The network helps show where Ruud Oerlemans may publish in the future.

Co-authorship network of co-authors of Ruud Oerlemans

This figure shows the co-authorship network connecting the top 25 collaborators of Ruud Oerlemans. A scholar is included among the top collaborators of Ruud Oerlemans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruud Oerlemans. Ruud Oerlemans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide 2018 ·Investigational New Drugs ·Ruud Oerlemans,Celia R. Berkers,Yehuda G. Assaraf,George L. Scheffer,Godefridus J. Peters,Sue Ellen Verbrugge,Jacqueline Cloos,Jerry W. Slootstra,Rob H. Meloen,Robert H. Shoemaker,Ben A. C. Dijkmans,Rik J. Scheper,Huib Ovaa,Gerrit Jansen	6
2	THU0185 The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate 2018 ·Annals of the Rheumatic Diseases ·Josef S Smolen,Nael M. Mostafa,Xin Huang,Peter Noertersheuser,(unknown),(unknown),Jasmina Kalabic,(unknown),Ruud Oerlemans,S. Florentinus,Gerd R Burmester	2
3	Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients 2013 ·Scandinavian Journal of Rheumatology ·(unknown),(unknown),A. Gerards,Ruud Oerlemans,(unknown),RJ Scheper,(unknown),Gerrit Jansen	12
4	Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Sue Ellen Verbrugge,Yehuda G. Assaraf,Ben A. C. Dijkmans,George L. Scheffer,(unknown),Debby den Uyl,Ruud Oerlemans,Elena T. Chan,Christopher J. Kirk,Godefridus J. Peters,Joost W van der Heijden,Tanja D. de Gruijl,Rik J. Scheper,Gerrit Jansen	87
5	The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage 2012 ·Cell Biology and Toxicology ·A. van Dijk,Benno A. Naaijkens,Wouter J.F.M. Jurgens,Ruud Oerlemans,George L. Scheffer,(unknown),(unknown),Mieke C. Brouwer,Albert C. van Rossum,Gerrit‐Jan Schuurhuis,Florine J. van Milligen,Hans W.M. Niessen	10
6	T lymphocytes impair P-glycoprotein function during neuroinflammation 2009 ·Journal of Autoimmunity ·Gijs Kooij,Jack van Horssen,Elizabeth C. M. de Lange,Arie Reijerkerk,Susanne M. A. van der Pol,Bert van het Hof,Joost Drexhage,Anke Vennegoor,Joep Killestein,George L. Scheffer,Ruud Oerlemans,Rik J. Scheper,Paul van der Valk,Christine D. Dijkstra,Helga E. de Vries	48
7	Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide 2009 ·Arthritis & Rheumatism ·Joost W van der Heijden,Ruud Oerlemans,Paul P. Tak,Yehuda G. Assaraf,Maarten C. Kraan,George L. Scheffer,Conny J. van der Laken,Willem F. Lems,Rik J. Scheper,Ben A. C. Dijkmans,Gerrit Jansen	54
8	The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. 2009 ·PubMed ·Joost W van der Heijden,Ruud Oerlemans,Willem F. Lems,Rik J. Scheper,Ben A. C. Dijkmans,Gerrit Jansen	49
9	Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients 2008 ·Arthritis & Rheumatism ·Joost W van der Heijden,Ruud Oerlemans,Ben A. C. Dijkmans,Huiling Qi,Conny J. van der Laken,Willem F. Lems,Ann L. Jackman,Maarten C. Kraan,Paul P. Tak,Manohar Ratnam,Gerrit Jansen	127
10	A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration 2008 ·Blood ·Rieneke van de Ven,George L. Scheffer,Anneke W. Reurs,Jelle J. Lindenberg,Ruud Oerlemans,Gerrit Jansen,Jean‐Pierre Gillet,Joel N. Glasgow,Alexander Pereboev,David T. Curiel,Rik J. Scheper,Tanja D. de Gruijl	51
11	Acquisition of Mutations in the PSMB5 Gene during Chronic Exposure of Human Acute Lymphoblastic Leukemia CCRF-CEM Cells to the Proteasome Inhibitor Bortezomib 2008 ·Blood ·N. Franke,Ruud Oerlemans,Ina van Zantwijk,(unknown),Gertjan J.L. Kaspers,Gerrit Jansen,Jacqueline Cloos	0
12	Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein 2008 ·Blood ·Ruud Oerlemans,N. Franke,Yehuda G. Assaraf,Jacqueline Cloos,Ina van Zantwijk,Celia R. Berkers,George L. Scheffer,(unknown),(unknown),Clara Lemos,Joost W van der Heijden,Bauke Ylstra,Godefridus J. Peters,Gertjan J.L. Kaspers,Ben A. C. Dijkmans,Rik J. Scheper,Gerrit Jansen	357
13	Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor α and glucocorticoid induced apoptosis 2007 ·Annals of the Rheumatic Diseases ·Ruud Oerlemans,(unknown),B.A.C. Dijkmans,Yehuda G. Assaraf,(unknown),(unknown),Ilan Ifergan,Willem F. Lems,R J Scheper,Gertjan J.L. Kaspers,Jacqueline Cloos,Gerrit Jansen	12
14	Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells. 2007 ·Blood ·N. Franke,Ruud Oerlemans,Sonja Zweegman,Ina van Zantwijk,Gertjan J.L. Kaspers,Gerrit Jansen,Jacqueline Cloos	2
15	Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance–associated protein 1 and provokes high levels of cross‐resistance to glucocorticoids 2006 ·Arthritis & Rheumatism ·Ruud Oerlemans,(unknown),(unknown),Ben A. C. Dijkmans,Gertjan J.L. Kaspers,Willem F. Lems,George L. Scheffer,Ilan Ifergan,Rik J. Scheper,Jacqueline Cloos,Yehuda G. Assaraf,Gerrit Jansen	31
16	Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography 2006 ·Clinical Pharmacology & Therapeutics ·(unknown),(unknown),Gert Luurtsema,Mark Lubberink,(unknown),Tessa M. Bosch,Ruud Oerlemans,Adriaan A. Lammertsma,Eric J. F. Franssen	141
17	Inhibition of tumour necrosis factor alpha production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study 2005 ·Arthritis Research ·(unknown),A. Gerards,Ruud Oerlemans,(unknown),RJ Scheper,LA Aarden,B.A.C. Dijkmans,Gerrit Jansen	2
18	Differential expression of multidrug resistance-related proteins on monocyte-derived macrophages from rheumatoid arthritis patients 2005 ·Arthritis Research ·Ruud Oerlemans,B. A. C. Dijkmans,(unknown),W.F. Lems,Anneke W. Reurs,(unknown),(unknown),Gerrit Jansen	3
19	Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in rheumatoid arthritis 2004 ·Arthritis & Rheumatism ·Gerrit Jansen,(unknown),Ruud Oerlemans,Willem F. Lems,Ilan Ifergan,Rik J. Scheper,Yehuda G. Assaraf,Ben A. C. Dijkmans	56
20	Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells 2004 ·Molecular Pharmacology ·Michiel de Bruin,Godefridus J. Peters,Ruud Oerlemans,Yehuda G. Assaraf,Allan J. Masterson,(unknown),Ben A. C. Dijkmans,Herbert M. Pinedo,Gerrit Jansen	15

About Ruud Oerlemans

Ruud Oerlemans is a scholar working on Hematology, Rheumatology and Oncology, having authored 23 papers that have together received 1.2k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (8 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and Multiple Myeloma Research and Treatments (5 papers). The work is most often cited by research in Hematology (305 citations), Oncology (445 citations) and Rheumatology (153 citations). Ruud Oerlemans has collaborated with scholars based in Netherlands, Israel and United States. Frequent co-authors include Gerrit Jansen, Rik J. Scheper, Ben A. C. Dijkmans, Joost W van der Heijden, George L. Scheffer, Yehuda G. Assaraf, Willem F. Lems, Godefridus J. Peters, Jacqueline Cloos and Gertjan J.L. Kaspers. Their work appears in journals such as Blood, Journal of Pharmacology and Experimental Therapeutics and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact